ACADIA Pharmaceuticals stock falls after negative EU regulatory vote on Rett drug By Investing.com
ACADIA Pharmaceuticals stock falls after negative EU regulatory vote on Rett drug…
24,755$
-5,26%
Echtzeit-Aktienkurs Acadia Pharmaceuticals Inc.
Bid:
Ask:
Nachrichten zur Acadia Pharmaceuticals Inc. Aktie
NRx Pharmaceuticals (Nasdaq:NRXP) Announces 70,000 Patient Data on Real World Use of Ketamine for Treatment of Suicidal Depression to be Submitted to the FDA in Support of NRX-100 Approval
WILMINGTON, Del., Jan. 14, 2026 (GLOBE NEWSWIRE) -- NRx Pharmaceuticals, Inc. (Nasdaq: NRXP), a clinical-stage biopharmaceutical company, today…
Heres Why Acadia Pharmaceuticals (ACAD) is a Strong Momentum Stock
Whether youre a value, growth, or momentum investor, finding strong stocks becomes easier with the Zacks Style Scores, a top…
Heres Why Acadia Pharmaceuticals (ACAD) is a Strong Momentum Stock
The Zacks Style Scores offers investors a way to easily find top-rated stocks based on their investing style. Heres why…
NRx Pharmaceuticals, Inc. (NASDAQ:NRXP) Reports Third Quarter 2025 Financial Results and Provides Corporate Update
WILMINGTON, Del., Nov. 17, 2025 (GLOBE NEWSWIRE) -- NRx Pharmaceuticals, Inc. (Nasdaq: NRXP) (“NRx Pharmaceuticals,” the “Company”), a…
Acadia Pharmaceuticals director Daly sells $670k in stock By Investing.com
Acadia Pharmaceuticals director Daly sells $670k in stock…
Why Acadia Pharmaceuticals (ACAD) is a Top Momentum Stock for the Long-Term
The Zacks Style Scores offers investors a way to easily find top-rated stocks based on their investing style. Heres why…
This ACADIA Pharmaceuticals Analyst Begins Coverage On A Bullish Note; Here Are Top 5 Initiations For Tuesday - Hims & Hers Health (NYSE:HIMS), ACADIA Pharmaceuticals (NASDAQ:ACAD)
…
HOPE Therapeutics, Inc. and NRx Pharmaceuticals, Inc. (NASDAQ:NRXP) Announce Inclusion of Cohen & Associates, LLC of Sarasota, FL into the HOPE Network and Appointment of Dr. Rebecca Cohen as HOPE Medical Director
MIAMI, Oct. 20, 2025 (GLOBE NEWSWIRE) -- HOPE Therapeutics™, Inc. ("HOPE"), an interventional psychiatry network owned by NRx…
ACAD Stock Down 10% Following Phase III Hyperphagia Study Failure
Acadia Pharmaceuticals stock tumbles 10% after its phase III hyperphagia study failure, but growth remains driven by Nuplazid, Daybue and…
Acadia Pharmaceuticals: Reeling After PWS Failure - Downgrading To Hold
…
Ionis Pharmaceuticals Aktienanalyse: Tryngolza und Dawnzera starten durch - Raymond James passt Kursziel an!
Bad Marienberg (www.aktiencheck.de)???? Ionis Pharmaceuticals begeistert Analysten: Raymond James hebt Kursziel auf 75 USD - "strong buy"Ionis Pharmaceuticals Inc. (ISIN:…
Kaufalarm bei Acadia Pharmaceuticals (ACAD): Innovationsführer in der Neurotherapie mit starkem Wachstumspotenzial!
Acadia Pharmaceuticals (ACAD) widmet sich insbesondere der Behandlung von Parkinson-Psychose, dem Rett-Syndrom und der Alzheimer-Psychose. Die Parkinson-Psychose (PDP) betrifft etwa…
Acadia Pharmaceuticals: Another Legal Win, ACP-101 Readout Preview
…
NRx Pharmaceuticals, Inc. (NRXP) Q1 2025 Earnings Call Transcript
…
Acadia Pharmaceuticals shares surge on patent ruling By Investing.com
Acadia Pharmaceuticals shares surge on patent ruling…
Adial Pharmaceuticals Reports First Quarter 2025 Financial Results and Provides Business Update
GLEN ALLEN, Va., May 15, 2025 (GLOBE NEWSWIRE) -- Adial Pharmaceuticals, Inc. (NASDAQ: ADIL) (“Adial” or the “Company”),…
Acadia Pharmaceuticals (ACAD) Tops Q1 Earnings and Revenue Estimates (Revised)
Acadia (ACAD) delivered earnings and revenue surprises of 10% and 1.23%, respectively, for the quarter ended March 2025. Do the…
Adial Pharmaceuticals Announces a Warrant Inducement Transaction for $2.75 Million in Gross Proceeds
GLEN ALLEN, Va., May 02, 2025 (GLOBE NEWSWIRE) -- Adial Pharmaceuticals, Inc. (NASDAQ: ADIL) (“Adial” or the “Company”),…
NRx Pharmaceuticals, Inc. (NRXP) Q4 2024 Earnings Call Transcript
…
Adial Pharmaceuticals Reports 2024 Fiscal Year Financial Results and Provides Business Update
GLEN ALLEN, Va., March 04, 2025 (GLOBE NEWSWIRE) -- Adial Pharmaceuticals, Inc. (NASDAQ: ADIL) (“Adial” or the “Company”),…
BioStock: Saniona strengthened its cash position and advanced through partnership
Saniona’s key milestone in 2024 was securing an exclusive worldwide licensing agreement with Acadia Pharmaceuticals worth up to USD 610…
Acadia Pharmaceuticals (ACAD) Q4 Earnings Lag Estimates
Acadia (ACAD) delivered earnings and revenue surprises of -10.53% and 1.79%, respectively, for the quarter ended December 2024. Do the…
BioStock: Saniona’s CEO responds to investors’ questions
Saniona’s collaboration with Acadia Pharmaceuticals, signed in November, marked a significant milestone for the company. With a total potential value…
Acadia Pharmaceuticals: DAYBUE steht vor Alleinstellung in der EU, den USA und Kanada
Die Aktie von Acadia Pharmaceuticals befindet sich bereits seit langer Zeit auf der Watchlist für unser Frühwarnsystem. Seit ich diese…
Saniona’s CEO to BioStock: “The deal with Acadia is significant”
Saniona has announced a partnership with Acadia Pharmaceuticals to develop and commercialize SAN711. The total potential deal size is USD…
NRx Pharmaceuticals, Inc. (NRXP) Q3 2024 Earnings Call Transcript
…
ACADIA Pharmaceuticals Inc. (ACAD) Q3 2024 Earnings Conference Call Transcript
…
ACADIA Pharmaceuticals Inc. 2024 Q3 - Results - Earnings Call Presentation
…
Acadia Pharmaceuticals: Nuplazid Performs In Q2 While Daybue Disappoints Again
…
NRx Pharmaceuticals, Inc. (NRXP) Q2 2024 Earnings Call Transcript
…
ACADIA Pharmaceuticals Inc. 2024 Q2 - Results - Earnings Call Presentation
…
Acadia Pharmaceuticals: Back In The Buy Zone
…
Acadia Pharmaceuticals: Bullish On Nuplazid And Daybue Driven Growth In CNS Treatments
…
Adial Pharmaceuticals Reports First Quarter 2024 Financial Results and Provides Business Update
GLEN ALLEN, Va., May 15, 2024 (GLOBE NEWSWIRE) -- Adial Pharmaceuticals, Inc. (NASDAQ: ADIL) (“Adial” or the “Company”),…
NRx Pharmaceuticals, Inc. (NRXP) Q1 2024 Earnings Call Transcript
…
ACADIA Pharmaceuticals Inc. (ACAD) Q1 2024 Earnings Call Transcript
…
ACADIA Pharmaceuticals Inc. 2024 Q1 - Results - Earnings Call Presentation
…
Biotech Stock Roundup: AMLX, ACAD Down on Study Data, MRNA, RGLS Gain on Updates & More
Amylyx Pharmaceuticals (AMLX) and Acadia Pharmaceuticals (ACAD) plunged on failure of studies.…
Acadia Pharmaceuticals: Post Pimavanserin Study Setback Selloff May Continue
…
Adial Pharmaceuticals Announces Exercise of Warrants for $3.5 Million Gross Proceeds
CHARLOTTESVILLE, Va., March 01, 2024 (GLOBE NEWSWIRE) -- Adial Pharmaceuticals, Inc. (NASDAQ: ADIL) (“Adial” or the “Company”), a…
Acadia Pharmaceuticals: New Daybue Drug Already Showing Signs Of Slowing
…
Acadia Pharmaceuticals: Daybue Growth Concerns, Important Data Readout Coming
…
ACADIA Pharmaceuticals Inc. (ACAD) Q4 2023 Earnings Call Transcript
…
ACADIA Pharmaceuticals Inc. 2023 Q4 - Results - Earnings Call Presentation
…